Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...

JuliaHub simplifies complex pharmaceutical workflows by integrating analytics such as modeling and simulation in pharmacometrics. Unlike fragmented systems, it ensures seamless transitions between ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, ...

In this Pharmaceutical Executive video interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses ...

When Genentech licensed experimental drug vixarelimab from Kiniksa Pharmaceuticals KNSA0.51%increase; green up pointing triangle, its scientists thought they had a future lung medicine in their hands.